Latest Spliceosome Stories
Fetuses with defects in a molecular machine that edits information cells use to make proteins can develop a rare form of dwarfism.
Grant Funds Work of Ronald G. Victor, M.D.
Zebrafish study highlights existing drugs that may help restore muscle in DMD BOSTON, March 18, 2011 /PRNewswire-USNewswire/ -- Armed with a zebrafish model of Duchenne muscular dystrophy (DMD) and a library of 1,200 chemicals already approved for human use, researchers at Children's Hospital Boston have identified a compound that reverses the loss of muscle structure and function associated with DMD, seemingly by compensating for the loss of a critical protein.
From neurosurgery to bar code readers, lasers have been used in a myriad of applications since they were first introduced in the late 1950's.
Scientists at the University of Pennsylvania explain how a class of RNA molecules is able to target the genetic building blocks that guide the functioning of a specific part of the nerve cell.
AMSTERDAM, March 7, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy (DMD).
Efforts over decade result in $192 million in Duchenne-specific federal investment HACKENSACK, N.J., Feb.
It's a gene called DOT1L, and if you donâ€™t have enough of the DOT1L enzyme, you could be at risk for some types of heart disease.
DNA was originally thought to have a single function: to help cells make the proteins they need.
Scientists are reporting an advance in overcoming a major barrier to the use of the genetic material RNA in nanotechnology â€” the field that involves building machines thousands of times smaller than the width of a human hair and now is dominated by its cousin, DNA.